<DOC>
	<DOCNO>NCT01418430</DOCNO>
	<brief_summary>The purpose study determine safety combination CHOP plus daclizumab patient ATLL previously untreated anthracycline base chemotherapy .</brief_summary>
	<brief_title>Pilot Study Combination Therapy With CHOP-Zenapax ( CHOP-daclizumab )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Histologically confirm ATLL require treatment 1 . Frank acute leukaemia lymphoma subtypes 2 . Chronic smouldering case consider symptomatic require therapy , evidence disease progression 2 . No previous treatment anthracycline base cytotoxic chemotherapy . Patients may receive interferon /or zidovudine and/or nonanthracycline base therapy 3 . Age 1875 year 4 . Written inform consent 1 . HIV 1 2 positivity 2 . Pregnancy breastfeed 3 . Concomitant chemoradiotherapy 4 . Prior hepatic renal insufficiency bilirubin transaminases great 5 time normal range creatinine great 150Î¼mol/l ( related hypercalcaemia ) follow rehydration 5 . Other concomitant neoplasm relate HTLVI 6 . Cardiac respiratory insufficiency ECOG score great 3 7 . Any serious active uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>